126 related articles for article (PubMed ID: 37897887)
21. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
23. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
[TBL] [Abstract][Full Text] [Related]
24. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy in locally advanced nasopharyngeal carcinoma: Comparative study at SKIMS Tertiary Care Institute.
Fatima K; Andleeb A; Sofi MA; Rasool MT; Fir A; Nasreen S; Dar NA
J Cancer Res Ther; 2022; 18(1):133-139. PubMed ID: 35381774
[TBL] [Abstract][Full Text] [Related]
26. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
[TBL] [Abstract][Full Text] [Related]
28. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J
Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674
[TBL] [Abstract][Full Text] [Related]
29. Impact of comorbidity on tolerability and survival following curative intent intensity modulated radiotherapy in older patients with nasopharyngeal cancer.
Sommat K; Yit NLF; Wang F; Lim JHC
J Geriatr Oncol; 2018 Jul; 9(4):352-358. PubMed ID: 29429963
[TBL] [Abstract][Full Text] [Related]
30. Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
Wang G; Huang C; Yang K; Guo R; Qiu Y; Li W; Mao Y; Tang L; Ma J
Radiother Oncol; 2022 Dec; 177():205-213. PubMed ID: 36375564
[TBL] [Abstract][Full Text] [Related]
31. Effect of chemotherapy on survival in patients with stage T3-4N0M0 nasopharyngeal carcinoma.
Pan XB; Qu S; Li L; Chen L; Liang SX; Zhu XD
Clin Otolaryngol; 2021 Jul; 46(4):802-808. PubMed ID: 33580628
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis.
Chen YP; Mao YP; Zhang WN; Chen L; Tang LL; Li WF; Liu X; Zhou GQ; Guo R; Sun Y; Kang TB; Zeng MS; Ma J
Oncotarget; 2016 Mar; 7(12):14973-82. PubMed ID: 26942870
[TBL] [Abstract][Full Text] [Related]
33. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.
Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W
J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113
[TBL] [Abstract][Full Text] [Related]
34. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
[TBL] [Abstract][Full Text] [Related]
35. The impact of Adult Comorbidity Evaluation-27 on the clinical outcome of elderly nasopharyngeal carcinoma patients treated with chemoradiotherapy or radiotherapy: a matched cohort analysis.
Wen YF; Sun XS; Yuan L; Zeng LS; Guo SS; Liu LT; Lin C; Xie HJ; Liu SL; Li XY; Zhang YB; Huang WJ; Peng HH; Liao ZW; Song XL; Tang QN; Liang YJ; Yan JJ; Yang JH; Yang ZC; Chen QY; Lin XD; Tang LQ; Mai HQ
J Cancer; 2019; 10(23):5614-5621. PubMed ID: 31737097
[No Abstract] [Full Text] [Related]
36. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma.
OuYang PY; Shi D; Sun R; Zhu YJ; Xiao Y; Zhang LN; Zhang XH; Chen ZY; Lan XW; Tang J; Gao YH; Ma J; Deng W; Xie FY
Oncotarget; 2016 May; 7(22):33408-17. PubMed ID: 27058901
[TBL] [Abstract][Full Text] [Related]
37. Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas.
Du L; Zhang XX; Feng LC; Qu BL; Chen J; Yang J; Liu HX; Xu SP; Xie CB; Ma L
BMC Cancer; 2017 Aug; 17(1):582. PubMed ID: 28851315
[TBL] [Abstract][Full Text] [Related]
38. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
39. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
[TBL] [Abstract][Full Text] [Related]
40. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
Zhou L; Lin J; Chen J; Zhang S
J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
